Merck adds $300M, 180 jobs at NC plant; Novartis yanks pre-pandemic vaccine app;

> Color North Carolina pleased. Merck plans to invest an additional $300 million in a vaccine plant in Durham, N.C., expanding it beyond its original scope.

> When the interview subject is adversity, who better to question than Schering-Plough's Fred Hassan, who's seen his share this year? Report

> Bavarian Nordic says that an interim analysis of two clinical trials of its experimental breast cancer vaccine shows that the therapy appears to be well tolerated and immunogenic. Report

> Faced with a looming deadline to provide more data on the pre-pandemic vaccine Aflunov, Novartis Vaccines and Diagnostics has pulled its application for centralized marketing authorization from the European Medicines Agency. Report

> When British health officials weighed the benefits of the two cervical cancer vaccines, they concluded that Cervarix from GlaxoSmithKline provided the best value for the money. Report

> British ministers have ordered a review of antipsychotics, which have been linked to an increased risk of death in elderly patients with dementia. Report

> More government watchdogs appear to be boarding the Paxil investigation train. The Justice Department is coordinating a probe that includes Colorado's Justice folks and the Boston U.S. attorney's office. Report

And Finally... Thirty-two thousand veterans will soon find letters about Chantix in their mailboxes. Chantix report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.